363 related articles for article (PubMed ID: 27539844)
41. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
42. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
43. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Lohrmann C; Zhang H; Thorek DL; Desai P; Zanzonico PB; O'Donoghue J; Irwin CP; Reiner T; Grimm J; Weber WA
J Nucl Med; 2015 May; 56(5):805-11. PubMed ID: 25840974
[TBL] [Abstract][Full Text] [Related]
44. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
45. In Vivo 3-Dimensional Radiopharmaceutical-Excited Fluorescence Tomography.
Hu Z; Zhao M; Qu Y; Zhang X; Zhang M; Liu M; Guo H; Zhang Z; Wang J; Yang W; Tian J
J Nucl Med; 2017 Jan; 58(1):169-174. PubMed ID: 27660137
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer.
Lesniak WG; Boinapally S; Banerjee SR; Behnam Azad B; Foss CA; Shen C; Lisok A; Wharram B; Nimmagadda S; Pomper MG
Mol Pharm; 2019 Jun; 16(6):2590-2604. PubMed ID: 31002252
[TBL] [Abstract][Full Text] [Related]
47. Cerenkov imaging.
Das S; Thorek DL; Grimm J
Adv Cancer Res; 2014; 124():213-34. PubMed ID: 25287690
[TBL] [Abstract][Full Text] [Related]
48. β-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging.
King MT; Carpenter CM; Sun C; Ma X; Le QT; Sunwoo JB; Cheng Z; Pratx G; Xing L
J Nucl Med; 2015 Sep; 56(9):1458-64. PubMed ID: 26205301
[TBL] [Abstract][Full Text] [Related]
49. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
[TBL] [Abstract][Full Text] [Related]
50. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
[TBL] [Abstract][Full Text] [Related]
51. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.
Olafsen T; Betting D; Kenanova VE; Salazar FB; Clarke P; Said J; Raubitschek AA; Timmerman JM; Wu AM
J Nucl Med; 2009 Sep; 50(9):1500-8. PubMed ID: 19690034
[TBL] [Abstract][Full Text] [Related]
52.
Olde Heuvel J; de Wit-van der Veen BJ; van der Poel HG; Bekers EM; Grootendorst MR; Vyas KN; Slump CH; Stokkel MPM
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2624-2632. PubMed ID: 32242253
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL.
Natarajan A; Habte F; Liu H; Sathirachinda A; Hu X; Cheng Z; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2013 Aug; 15(4):468-75. PubMed ID: 23471750
[TBL] [Abstract][Full Text] [Related]
54. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
55. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
[TBL] [Abstract][Full Text] [Related]
56. PET imaging in urology: a rapidly growing successful collaboration.
Farolfi A; Koschel S; Murphy DG; Fanti S
Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
[TBL] [Abstract][Full Text] [Related]
57. Multimodal Molecular Imaging Reveals High Target Uptake and Specificity of 111In- and 68Ga-Labeled Fibrin-Binding Probes for Thrombus Detection in Rats.
Oliveira BL; Blasi F; Rietz TA; Rotile NJ; Day H; Caravan P
J Nucl Med; 2015 Oct; 56(10):1587-92. PubMed ID: 26251420
[TBL] [Abstract][Full Text] [Related]
58. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
59. Imaging of bacterial infection: Harnessing positron emission tomography and Cherenkov luminescence imaging with UBI-derived octapeptide.
Mitra JB; Mukherjee A; Kumar A; Chandak A; Rakshit S; Yadav HD; Pandey BN; Sarma HD
Drug Dev Res; 2023 Nov; 84(7):1513-1521. PubMed ID: 37571805
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the Accuracy of FMT/CT and PET/MRI for the Assessment of Antibody Biodistribution in Squamous Cell Carcinoma Xenografts.
Hage C; Gremse F; Griessinger CM; Maurer A; Hoffmann SHL; Osl F; Pichler BJ; Kiessling F; Scheuer W; Pöschinger T
J Nucl Med; 2018 Jan; 59(1):44-50. PubMed ID: 28848038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
